SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

Kendu Crypto is experiencing a surge in conversation fueled by its exceptionally active and dedicated community, which is relentlessly building a "permissionless brand" with numerous real-world products like Kendu Spice and Kendu Energy. This collective effort, marked by strong IRL initiatives and a long-term vision, sets KENDU apart, leading to a prevalent bullish sentiment across the crypto space.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is trending due to significant community anticipation surrounding its pivotal role in next-generation AI data centers, particularly with its advanced power solutions crucial for high-density computing infrastructure. The company's upcoming participation in a key industry conference is fueling discussions, as many investors speculate on potential news catalysts and the high short interest driving a prospective squeeze.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is trending amid intense debate, as investors grapple with its persistent stock decline despite new strategic AI partnerships and potential tailwinds from discussions around credit card interest rate caps. While many criticize management and predict further drops given recent analyst downgrades, a significant portion of the community views PYPL as profoundly undervalued, actively accumulating shares and anticipating a strong rebound.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRISPR Therapeutics is generating significant buzz following promising Phase 1 clinical data for CTX310, demonstrating deep and durable lipid reductions without serious adverse events. This breakthrough, published in The New England Journal of Medicine, validates the company's in vivo gene-editing platform and excites the community about its potential as a "one-and-done" treatment for severe lipid disorders. Investors anticipate substantial market recognition for this development, alongside ongoing pipeline progress in a field gaining new regulatory support.

Monero

Monero (XMR) is trending strongly as its community champions it as the 'king of privacy' and the 'real Bitcoin' amid growing global discourse on digital anonymity. Despite discussions around regulatory scrutiny of privacy tokens, XMR demonstrates significant momentum, with users emphasizing its superior decentralization and robust technology over alternatives.

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Amarin Corp - ADR

Amarin is generating significant conversation driven by intense speculation around a potential acquisition, especially as the J.P. Morgan conference fuels rumors of a strategic buyer like Novartis eyeing its cardiovascular assets. The community is also closely monitoring ongoing legal proceedings concerning patent validity, with recent delays sparking varied interpretations, while strong preliminary financial results showing positive cash flow are contributing to a cautious optimism about the company's future value.

Ribbon Acquisition Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on July 17, 2024 and is headquartered in Tokyo, Japan.

Ribbon Acquisition Corp. - Ordinary Shares - Class A

Ribbon Acquisition Corp. is attracting significant attention as a 'fresh SPAC,' with community discussions highlighting a recent vote and anticipation of a catalyst. Many are observing its small float and perceived low risk near its NAV, drawing comparisons to other SPACs that have seen rapid movements.

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Travere Therapeutics Inc

Travere Therapeutics is experiencing significant volatility and a pre-decision sell-off as the market reacts to the FDA's recent request for additional clarification on the clinical benefit of FILSPARI for the FSGS indication. While some investors view this information request as a strong signal for a potential Complete Response Letter or delay, leading to sharp declines, others are actively buying the dip, viewing the steep decline as an overreaction given the drug's strong efficacy and high unmet need. The community is actively debating whether this is a common regulatory step or a fundamental setback for a therapy poised to become the first approved treatment for FSGS, a rare kidney disorder.

BRC Group Holdings, Inc. engages in the provision of financial services and solutions to the capital raising and financial advisory needs of public and private firms. It operates through the following segments: Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications, and Consumer. The Capital Markets segment provides investment banking, corporate finance, research, wealth management, and sales and trading services to corporate, institutional, and high net worth clients. The Wealth Management segment offers retail brokerage, investment management, and insurance, and tax preparation services. The Financial Consulting segment focuses on a variety of specialized advisory services spanning bankruptcy, restructuring, turnaround management, forensic accounting, crisis and litigation support, appraisal and valuation, real estate, and operations management. The Auction and Liquidation segment deals with retail liquidation services. The Communications segment is composed of a portfolio of companies acquired for attractive risk-adjusted investment return characteristics. The Consumer segment includes Targus and the Brands investment portfolio. The company was founded in 1973 and is headquartered in Los Angeles, CA.

BRC Group Holdings Inc.

B. Riley Financial Inc

B. Riley Financial is generating significant buzz as investors anticipate the approaching deadline for its Q3 10-Q filing, crucial for regaining NASDAQ compliance. The community is actively discussing the stock's high short interest and low float, positioning it as a prime candidate for a short squeeze. This is complemented by a strong turnaround narrative, highlighted by recent debt restructuring, reported profitability, and increasing asset values, driving widespread optimism.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics (MLTX) is a hot topic after receiving positive FDA feedback, indicating that existing trial data for its lead drug, sonelokimab, is sufficient for a Biologics License Application in hidradenitis suppurativa. This significant de-risking of the regulatory pathway is igniting broad community speculation about potential acquisition interest from major pharmaceutical players and is driving analyst upgrades and re-ratings. The conversation highlights the company's strong nanobody platform and "best-in-class" efficacy signals as crucial long-term value drivers.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Oyster Point Pharmaâ??s lead product candidate, OC-01, a highly selective nicotinic acetylcholine receptor (nAChR) agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. Dry eye disease is a chronic, progressive condition that impacts more than 30 million Americans and is growing in prevalence. OC-01â??s novel mechanism of action re-establishes tear film homeostasis by activating the trigeminal parasympathetic pathway to stimulate the glands and cells responsible for natural tear film production, known as the Lacrimal Functional Unit (LFU).

Oyster Point Pharma Inc

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

OYST
Oyster Point Pharma Inc

Feed

News

Sentiment

Fundamentals

Info

Latest OYST News

OYSTOyster Point Pharma Inc